Gastroenterologie
a hepatologie

Determination of C-peptide levels during a glucose tolerance test in patients with pancreatic cancer

Tatiana Novotná ^Orcid.org  , Marián Bátovský ^{Orcid.org  1}

+ Affiliation
¹ Gastroenterologická klinika SZU a UN Bratislava, Slovenská republika

Summary

The mechanism responsible for diabetes mellitus (DM) in patients with pancreatic cancer remains controversial. The aim of our study is to verify that pancreatic cancer patients had lower C-peptide levels during an oral glucose tolerance test (oGTT) than the control subjects, regardless of the presence of diabetes mellitus, since until now only a few similar studies have been published. Methods: In our study we analysed C-peptide response at 120 minutes during the oGTT in 29 patients with pancreatic cancer and 23 patients with chronic pancreatitis – control subjects. Results: C-peptide levels, observed at 120 minutes during the oGTT in patients with pancreatic cancer, were not lower than those of control subjects, and the difference was not statistically significant (p = 0.257). By means of the oGTT, we detected diabetes mellitus in 15 (51%) patients in the pancreatic cancer group and in nine (39%) control subjects. There were no statistically significant differences in C-peptide levels in patients with and without DM, or in the pancreatic cancer group (p = 0.383) or in control subjects with chronic pancreatitis (p = 0.877). Conclusions: We did not confirm that a characteristic feature of pancreatic cancer patients is decreased C-peptide production during the oGTT in comparison with the control subjects. Further studies are needed in a large number of patients to assess the importance of impaired glucose tolerance or diabetes mellitus in pancreatic cancer detection.

Keywords

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users